3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E-2 are a promising alternative for cancer immunotherapy

Yi, DH; Stetter, N; Jakobsen, K; Jonsson, R; Appel, S

Appel, S (reprint author), Univ Bergen, Broegelmann Res Lab, Dept Clin Sci, Jonas Lies Vei 87, N-5021 Bergen, Norway.

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018; 67 (10): 1611

Abstract

Numerous trials using dendritic cell (DC)-based vaccinations for the treatment of cancer are being carried out. However, an improvement of the quality......

Full Text Link